Akorn to Acquire Hi-Tech Pharmacal - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Akorn to Acquire Hi-Tech Pharmacal



The specialty pharmaceutical companies Akorn and Hi-Tech Pharmacal have formed an agreement under which Akorn will acquire Hi-Tech for $640 million in cash. The deal, which is subject to customary closing conditions, is scheduled to close in the first quarter of 2014. The combined company will have sales in excess of $500 million, according to an Akorn press statement.

Hi-Tech is a specialty pharmaceutical company developing, manufacturing, and marketing generic and branded prescription and over-the-counter (OTC) products. Hi-Tech specializes in difficult-to-manufacture liquid and semisolid dosage forms and produces and markets a range of oral solutions and suspensions as well as topical ointments and creams, nasal sprays, otics, sterile ophthalmics, sterile ointments, and gels products.

The acquisition strengthens Akorn’s position in generic ophthalmic drugs and also broadens its product offering to include other niche dosage forms such as oral liquids, topical creams and ointments, nasal sprays, and otics. The deal also enhances Akorn’s retail presence in both prescription and OTC products. Akorn says it plans to capitalize on the manufacturing capabilities of Hi-Tech to further expand its presence in the private-label OTC business. On a product basis, Akorn currently has 57 abbreviated new drug applications (ANDAs) filed with FDA, and Hi-Tech has filed 18 ANDAs.

Akorn expects to achieve between $15 million and $20 million in annual run-rate synergies within 12 months of close.

Source: Akorn

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here